Cargando…
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
BACKGROUND: Presenilin-1 (PS1) is the active component of the amyloid precursor protein cleaving γ-secretase complex. PS1 protein is a transmembrane protein containing multiple hydrophobic regions which presence in cerebrospinal fluid (CSF) has not been measured to date. This study assesses whether...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893612/ https://www.ncbi.nlm.nih.gov/pubmed/24252417 http://dx.doi.org/10.1186/2051-5960-1-46 |
_version_ | 1782299727881043968 |
---|---|
author | García-Ayllón, María-Salud Campanari, María-Letizia Brinkmalm, Gunnar Rábano, Alberto Alom, Jordi Saura, Carlos A Andreasen, Niels Blennow, Kaj Sáez-Valero, Javier |
author_facet | García-Ayllón, María-Salud Campanari, María-Letizia Brinkmalm, Gunnar Rábano, Alberto Alom, Jordi Saura, Carlos A Andreasen, Niels Blennow, Kaj Sáez-Valero, Javier |
author_sort | García-Ayllón, María-Salud |
collection | PubMed |
description | BACKGROUND: Presenilin-1 (PS1) is the active component of the amyloid precursor protein cleaving γ-secretase complex. PS1 protein is a transmembrane protein containing multiple hydrophobic regions which presence in cerebrospinal fluid (CSF) has not been measured to date. This study assesses whether PS1 and other components of the γ-secretase complex are present in CSF. RESULTS: Here, we show that PS1 is present in ventricular post-mortem and lumbar ante-mortem CSF, and plasma as 100–150-kDa hetero-complexes containing both the N- and C-terminal fragments (NTF and CTF) of the protein. Immunoprecipitation and immunoblotting with different antibodies confirmed the identity of the PS1 species. The γ-secretase components, APH-1 (anterior pharynx-defective 1) and PEN-2 (presenilin enhancer 2), as well as presenilin-2 (PS2) fragments, co-exist within these CSF complexes, while nicastrin is not detected. These CSF-PS1 complexes differ from active γ-secretase membrane-complexes, and may represent nonspecific aggregation of the PS1 protein. Levels of PS1 complexes are increased in CSF samples from autopsy-confirmed Alzheimer’s disease (AD) cases and were found to be more stable than complexes in CSF from control subjects. Despite similar levels of total PS1 in CSF from probable AD patients and cognitively normal subjects, an increased proportion of highly stable PS1 complexes were observed in AD CSF. CONCLUSIONS: Our data suggest that fragments of the PS1 protein present in CSF as complexes may be useful as a biomarker for AD. |
format | Online Article Text |
id | pubmed-3893612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38936122014-01-17 CSF Presenilin-1 complexes are increased in Alzheimer’s disease García-Ayllón, María-Salud Campanari, María-Letizia Brinkmalm, Gunnar Rábano, Alberto Alom, Jordi Saura, Carlos A Andreasen, Niels Blennow, Kaj Sáez-Valero, Javier Acta Neuropathol Commun Research BACKGROUND: Presenilin-1 (PS1) is the active component of the amyloid precursor protein cleaving γ-secretase complex. PS1 protein is a transmembrane protein containing multiple hydrophobic regions which presence in cerebrospinal fluid (CSF) has not been measured to date. This study assesses whether PS1 and other components of the γ-secretase complex are present in CSF. RESULTS: Here, we show that PS1 is present in ventricular post-mortem and lumbar ante-mortem CSF, and plasma as 100–150-kDa hetero-complexes containing both the N- and C-terminal fragments (NTF and CTF) of the protein. Immunoprecipitation and immunoblotting with different antibodies confirmed the identity of the PS1 species. The γ-secretase components, APH-1 (anterior pharynx-defective 1) and PEN-2 (presenilin enhancer 2), as well as presenilin-2 (PS2) fragments, co-exist within these CSF complexes, while nicastrin is not detected. These CSF-PS1 complexes differ from active γ-secretase membrane-complexes, and may represent nonspecific aggregation of the PS1 protein. Levels of PS1 complexes are increased in CSF samples from autopsy-confirmed Alzheimer’s disease (AD) cases and were found to be more stable than complexes in CSF from control subjects. Despite similar levels of total PS1 in CSF from probable AD patients and cognitively normal subjects, an increased proportion of highly stable PS1 complexes were observed in AD CSF. CONCLUSIONS: Our data suggest that fragments of the PS1 protein present in CSF as complexes may be useful as a biomarker for AD. BioMed Central 2013-08-06 /pmc/articles/PMC3893612/ /pubmed/24252417 http://dx.doi.org/10.1186/2051-5960-1-46 Text en Copyright © 2013 García-Ayllón et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research García-Ayllón, María-Salud Campanari, María-Letizia Brinkmalm, Gunnar Rábano, Alberto Alom, Jordi Saura, Carlos A Andreasen, Niels Blennow, Kaj Sáez-Valero, Javier CSF Presenilin-1 complexes are increased in Alzheimer’s disease |
title | CSF Presenilin-1 complexes are increased in Alzheimer’s disease |
title_full | CSF Presenilin-1 complexes are increased in Alzheimer’s disease |
title_fullStr | CSF Presenilin-1 complexes are increased in Alzheimer’s disease |
title_full_unstemmed | CSF Presenilin-1 complexes are increased in Alzheimer’s disease |
title_short | CSF Presenilin-1 complexes are increased in Alzheimer’s disease |
title_sort | csf presenilin-1 complexes are increased in alzheimer’s disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893612/ https://www.ncbi.nlm.nih.gov/pubmed/24252417 http://dx.doi.org/10.1186/2051-5960-1-46 |
work_keys_str_mv | AT garciaayllonmariasalud csfpresenilin1complexesareincreasedinalzheimersdisease AT campanarimarialetizia csfpresenilin1complexesareincreasedinalzheimersdisease AT brinkmalmgunnar csfpresenilin1complexesareincreasedinalzheimersdisease AT rabanoalberto csfpresenilin1complexesareincreasedinalzheimersdisease AT alomjordi csfpresenilin1complexesareincreasedinalzheimersdisease AT sauracarlosa csfpresenilin1complexesareincreasedinalzheimersdisease AT andreasenniels csfpresenilin1complexesareincreasedinalzheimersdisease AT blennowkaj csfpresenilin1complexesareincreasedinalzheimersdisease AT saezvalerojavier csfpresenilin1complexesareincreasedinalzheimersdisease |